Advances in Obesity and Diabetes Management: Highlights from ADA 2025
New weight-loss drug combinations, oral semaglutide cardiovascular outcomes, inhaled insulin for type 1 diabetes, and benefits of switching from diet drinks to water were key ADA 2025 findings.